Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2003-03-11
2009-06-30
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S009351, C424S646000, C424S647000, C424S648000, C514S023000, C514S054000, C514S059000
Reexamination Certificate
active
07553479
ABSTRACT:
Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.
REFERENCES:
patent: 2856366 (1958-10-01), Novak et al.
patent: 2856398 (1958-10-01), Novak et al.
patent: 2862920 (1958-12-01), Berger et al.
patent: 2885393 (1959-05-01), Herb
patent: 3000872 (1961-09-01), Novak
patent: 3151107 (1964-09-01), Heckel et al.
patent: 3234209 (1966-02-01), Floramo
patent: 4101435 (1978-07-01), Hasegawa et al.
patent: 4180567 (1979-12-01), Herb
patent: 4452773 (1984-06-01), Molday
patent: 4770183 (1988-09-01), Groman et al.
patent: 4827945 (1989-05-01), Groman et al.
patent: 5055288 (1991-10-01), Lewis et al.
patent: 5076950 (1991-12-01), Ullman et al.
patent: 5102652 (1992-04-01), Groman et al.
patent: 5160726 (1992-11-01), Groman et al.
patent: 5204457 (1993-04-01), Maruno et al.
patent: 5262176 (1993-11-01), Palmacci et al.
patent: 6165378 (2000-12-01), Maruno et al.
patent: 6291440 (2001-09-01), Andreasen et al.
patent: 0 230 768 (1986-12-01), None
patent: 0 450 092 (1991-10-01), None
patent: 1019513 (1966-02-01), None
patent: WO 91 09678 (1991-07-01), None
patent: WO 96 09840 (1996-04-01), None
patent: WO 9808899 (1998-03-01), None
patent: WO 00 30657 (2000-06-01), None
Chemical Abstracts, “Characterization of Ultrasmall, Paramagnetic Magnetite Particles as Superparamagnetic Contrast Agents in MRI,” 2000:671521 (Caplus Copyright 2001 ACS).
Patruta, et al., “Neutrophil Impairment Associated with Iron Therapy in Hemodialysis with Functional Iron Deficiency,”Journal of the American Society of Nephrology, 1988, pp. 655-663.
Gutteridge, J., “Radical-Promoting Loosely-Bound Iron in Biological Fluids and the Bleomycin Assay,”Life Chemistry Reports, 1987, vol. 4, pp. 113-142.
Am. Soc. Neph. Nov. 1997, “Dialysis Epidemiology, Outcomes and Clinical Trials,” Codes: FC—Free Communications; PD—Poster Discussions; PS—Poster Session.
Bullen, J., “The Significance of Iron in Infection,”Reviews of Infectious Diseases, vol. 3, No. 6, 1981; pp. 1127-1138.
Weinberg, E., “Iron and Infection,”Microbiological Reviews, Mar. 1978, vol. 42, No. 1, pp. 45-66.
Sweder, B, et al., “Effect of Iron (III) in the Presence of Various Ligands on the Phagocytic and Metabolic Activity of Human Polymorphonuclear Leukocytes,”The Journal of Immunology, vol. 132, No. 2, Feb. 1984, pp. 851-856.
Evan, P., et al, “Measurement of Iron and Copper in Biological Systems: Bleomycin and Copper-Phenanthroline Assays,”Methods of Enzymology, vol. 233, 1994, pp. 82-92.
Anaizi, N., “Parenteral Iron Supplementation,”The Drug Monitor—Parenteral(IV)Iron Supplementation, http://www.thedrugmonitor.com/iron.html; May 20, 2003; pp. 1-4.
Briseid, G., et al., “Dextran-Induced Anaphylactoid Reaction in Man: Altered Reactivity of High Molecular Weight Kininogen,”Acta Pharmacol. Et toxicol., 1980, 47:119-126.
Bruckner, G., “Organic Chemistry: Amino Acids, Peptides, and Carbohydrates,” Budapest: Tankonykiado Press, 1974.
Grimm, Jan, et al., “Characterization of Ultrasmall, Paramagnetic Magnetite Particles as Superparamagnetic Contrast Agents in MRI,” Database Chemabs [Online]:Invest. Radiol., 2000, vol. 35(9), pp. 553-556.
Hanna, C.H., et al., “Effect of Ether and Barbiturate Anesthesia on the Reaction of Rats to Dextran and of Dogs to Polyvinylpyrrolidone,”Am. J. Physiol. 1957, 191:615.
Hasegawa, et al., “Biological Behavior of Dextran-Iron Oxide Magnetic Fluid Injected Intravenously in Rats,”Japan J. Appl. Phys., 1998, Part I:37(3A):1029.
Hedin, H., et al., “Prevention of Dextran Anaphylaxis,”Int. Arch. Allergy and Immunol., 1997:113:358-359.
Jue, C.K., et al., “Determination of Reducing Sugars in the Nanomole Range with Tetrazolium Blue,”J. Biochem. Biophys. Methods, 1985, 11:109-15.
Kitchen, R., “Total Polysaccharide Test and Quantitative Method for Dextran,”Proc. Sugar Process. Res. Conf., 1983, 232-47.
Kumar, K., “Iron Assay and Size Exclusion High Performance Liquid Chromatography of Ferritin and Magnetoferritin,”J. Liq. Chromatogr. Relat. Technol., 1997, 20, 3351-3364.
Squire, J.R., et al., “Dextran, Its Properties and Use in Medicine” Charles C. Thomas, Springfield, IL, 1955.
Voorhees, A.B., et al., “Reactions of Albino Rats to Injections of Dextran,”Proc. Soc. Exp. Biol. Med., 1951, 76:254.
Wooding, et al., “Protein and Carbohydrates as Alternative Surfactants for the Preparation of Stable Magnetic Fluids,”IEEE Transactions on Magnetics, vol. 24, No. 2, Mar. 1998, pp. 1650-1652.
Bengele Howard
Frigo Timothy B.
Groman Ernest V.
Lewis Jerome M.
Paul Kenneth G.
AMAG Pharmaceuticals, Inc.
Bromberg & Sunstein LLP
Claytor Renee
Padmanabhan Sreeni
LandOfFree
Heat stable colloidal iron oxides coated with reduced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heat stable colloidal iron oxides coated with reduced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heat stable colloidal iron oxides coated with reduced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4104114